Zheng Xiao-li, Xu Le
Department of Gastroenterology, Beijing Hospital, Beijing 100730, China.
Email:
Zhonghua Yi Xue Za Zhi. 2013 Nov 26;93(44):3496-9.
To evaluate the efficacy and tolerability of a furazolidone-based quadruple rescue regimen in patients with previously failed Helicobacter pylori (H.pylori) eradication treatment.
A total of 156 patients were recruited from July 2011 to June 2013 at Beijing Hospital and randomized into one of the following 10-day treatment regimens: (1) Esomeprazole 20 mg twice daily, furazolidone 100 mg twice daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days. (2) Esomeprazole 20 mg twice daily, levofloxacin 500 mg daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days. H.pylori status was re-assessed with the (13)C-urea breath test at 4 weeks after the end of therapy.
The intention-to-treat (ITT) and per-protocol (PP) H.pylori eradication rates were 83.8% (67/80) and 88.2% (67/76) in the furazolidone-based quadruple group, and 69.7% (53/76) and 73.6% (53/72) in the levofloxacin-based quadruple group respectively (χ(2) = 4.311, 5.100; P = 0.038, 0.024).
The 10-day furazolidone-based quadruple therapy is an efficacious rescue strategy in patients with previously failed eradication therapy.
评估以呋喃唑酮为基础的四联挽救方案对先前幽门螺杆菌（H.pylori）根除治疗失败患者的疗效和耐受性。
2011年7月至2013年6月期间，在北京医院招募了156例患者，并将其随机分为以下10天治疗方案之一：（1）埃索美拉唑20毫克，每日两次；呋喃唑酮100毫克，每日两次；阿莫西林1000毫克，每日两次；铋盐150毫克，每日三次，共10天。（2）埃索美拉唑20毫克，每日两次；左氧氟沙星500毫克，每日一次；阿莫西林1000毫克，每日两次；铋盐150毫克，每日三次，共10天。治疗结束4周后，采用（13）C-尿素呼气试验重新评估H.pylori状态。
以呋喃唑酮为基础的四联组意向性治疗（ITT）和符合方案（PP）的H.pylori根除率分别为83.8%（67/80）和88.2%（67/76），以左氧氟沙星为基础的四联组分别为69.7%（53/76）和73.6%（53/72）（χ² = 4.311，5.100；P = 0.038，0.024）。
对于先前根除治疗失败的患者，10天的以呋喃唑酮为基础的四联疗法是一种有效的挽救策略。
